Immune thrombocytopenia (ITP) is caused by the immune system mistakenly attacking and destroying the body’s own platelets, the tiny blood cells responsible for clotting. In most cases, the immune system produces antibodies that latch onto platelets and mark them for destruction, primarily in the spleen. But platelet destruction is only part of the story. The same immune attack also disrupts the bone marrow’s ability to make new platelets, creating a double hit that drives platelet counts dangerously low.
How the Immune System Destroys Platelets
The core problem in ITP is a case of mistaken identity. The immune system generates IgG antibodies that bind to proteins on the platelet surface, particularly two abundant molecules called GPIIb/IIIa and GPIb-IX-V. These proteins are essential for normal platelet function, and they happen to be plentiful enough to become easy targets.
Once antibodies coat a platelet, immune cells called phagocytes recognize the antibody tags and consume the platelet. This destruction happens primarily in the spleen, which acts as a filter for the bloodstream. The spleen is also where the rogue immune cells that drive ITP are activated. B cells in the spleen’s red pulp show higher-than-normal rates of division in people with ITP, essentially churning out more of the destructive antibodies. This is why surgical removal of the spleen remains one of the most effective treatments for stubborn cases.
The Bone Marrow Problem
For years, ITP was understood purely as a destruction problem. The body makes platelets at a normal rate, but they get wiped out too fast. Research now shows that’s incomplete. The same autoantibodies that destroy circulating platelets also attack the bone marrow cells responsible for producing them, called megakaryocytes.
Megakaryocytes express the same surface proteins that platelets do, so they become targets for the same antibodies. When those antibodies bind to megakaryocytes, they interfere with nearly every step of platelet production: the cells can’t mature properly, they can’t migrate to the right location within the bone marrow, and they can’t form the long, branching extensions (called proplatelets) that eventually break off into individual platelets. Lab studies show that plasma from ITP patients reduces proplatelet formation in a dose-dependent way, and the proplatelets that do form are shorter and less branched than normal.
On top of this, cytotoxic T cells (a different arm of the immune system) can directly kill megakaryocytes in the bone marrow. So the body loses platelets faster than normal while simultaneously making fewer replacements.
Primary Versus Secondary ITP
When no underlying cause can be identified, the condition is called primary ITP. When low platelets develop as a consequence of another disease, infection, or medication, it’s called secondary ITP. The distinction matters because treating the underlying cause in secondary ITP can sometimes resolve the platelet problem entirely.
Viral and Bacterial Triggers
Infections are among the most common triggers for secondary ITP. The leading viral culprits include hepatitis C, cytomegalovirus (CMV), Epstein-Barr virus (the virus behind mono), HIV, and parvovirus B19. In children, ITP often appears a few weeks after an ordinary viral illness, which is why pediatric cases frequently resolve on their own as the infection clears.
A bacterial infection that deserves special attention is Helicobacter pylori, the stomach bacterium linked to ulcers. In one study, 51% of ITP patients tested positive for active H. pylori infection. Among those who were successfully treated with antibiotics, 68% achieved a lasting platelet recovery over a median follow-up of five years. Treating H. pylori in patients who tested negative for it produced no improvement, confirming that eliminating the bacterium itself, not the antibiotics, was responsible for the benefit. Guidelines now recommend testing for H. pylori in adults diagnosed with ITP.
Autoimmune Diseases
ITP frequently shows up alongside other autoimmune conditions. Systemic lupus erythematosus (SLE) is the most well-known association. Thrombocytopenia is a common blood-related complication of lupus, though severe drops (below 50,000 platelets per microliter) occur in roughly 3 to 10% of lupus patients. Antiphospholipid syndrome, which causes abnormal blood clotting, also overlaps significantly with ITP. Thrombocytopenia develops in 20 to 50% of people with antiphospholipid syndrome. Evans syndrome, a condition in which the immune system destroys both platelets and red blood cells, is another related disorder.
Medications That Can Trigger ITP
Dozens of medications can provoke an immune response against platelets. The mechanism was first recognized over a century ago in patients taking quinine for malaria, who sometimes developed sudden, severe bleeding that stopped when the drug was discontinued. Quinine remains one of the best-documented offenders.
A systematic review identified about 51 drugs as definite causes of drug-induced immune thrombocytopenia and another 17 as probable causes. The major categories include:
- Quinine and quinidine: the most thoroughly studied triggers
- Antibiotics: particularly sulfamethoxazole and vancomycin, with ceftriaxone and several others also implicated
- Anti-inflammatory drugs: various nonsteroidal anti-inflammatory medications
- Anticonvulsants and sedatives
- Heparin: technically the most common drug-associated cause of low platelets, though heparin-induced thrombocytopenia works through a distinct mechanism and causes clotting rather than bleeding
In drug-induced cases, platelet counts typically recover after the offending medication is stopped.
Vaccines and ITP
A small number of vaccines have been linked to ITP, most notably the MMR (measles, mumps, rubella) vaccine, which carries an estimated incidence of 0.087 to 4 cases per 100,000 doses, mostly in children. COVID-19 vaccines were also associated with thrombocytopenia at a rate of 0.80 to 11.3 cases per million doses, with no difference between sexes. Other vaccines, including those for hepatitis B, HPV, chickenpox, and pneumococcus, have been associated with ITP in case reports, but only MMR and COVID-19 vaccines have enough evidence to establish a clear temporal relationship. Vaccine-triggered ITP in children is usually self-limiting.
Who Gets ITP
ITP affects both children and adults, but the patterns differ. In children, the incidence is about 5.7 cases per 100,000 people per year, and the condition often follows a viral illness, appearing suddenly and resolving within weeks to months. In adults, the overall incidence is 3.8 per 100,000 per year, and the disease more often becomes chronic.
Among adults, women are significantly more likely to develop ITP than men, with a 48% higher incidence rate. This sex difference mirrors the pattern seen in many autoimmune diseases and is thought to relate to hormonal and genetic differences in immune regulation. The gap is most pronounced during reproductive years and narrows in older age groups.
Genetic Susceptibility
ITP is not directly inherited, but certain genetic variations appear to increase susceptibility. Much of this research comes from Asian populations, where links between specific immune-system genes (HLA class II alleles) and ITP risk have been identified. Attempts to replicate these findings in Western populations have largely failed, suggesting the genetic component may vary across ethnic groups.
Beyond HLA genes, researchers have identified variations in genes that regulate immune checkpoints and inflammation. Polymorphisms in genes controlling proteins like CTLA-4 (which normally puts the brakes on immune responses) have been linked to more severe bleeding and lower platelet counts at diagnosis. Variations in a gene called FCGR3A, which affects how immune cells recognize antibody-coated targets, have been associated with a higher risk of ITP in both children and adults. These findings point to an inherited tendency toward immune overactivation, though no single gene determines whether someone will develop ITP.